ASRS’s Journal of Vitreoretinal Diseases (JVRD) Author’s Forum

Biosimilar Ranibizumab (Ranieyes) Safety and Efficacy in the Real World: BRESER Study

• American Society of Retina Specialists (ASRS)

Share episode

Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.

0:00 | 12:39

On this episode of the JVRD Author's Forum podcast, Dr. David Eichenbaum of Retina Vitreous Associates of Florida discusses "Biosimilar Ranibizumab (RaniEyes) Safety and Efficacy in the Real World: BRESER Study," published in the May/June 2025 issue of JVRD. 

Host Dr. Timothy Murray and Dr. Eichenbaum talk about how biosimilars are developed and approved, and why real-world data is essential for evaluating their safety and effectiveness on a large scale. Learn why cost, access, and post-market surveillance are important factors in the growing role of biosimilars in retina care.

For more information, visit www.ASRS.org/JVRDForum.

Welcome to ASRS’s Journal of Vitreoretinal Diseases (JVRD) Author’s Forum. JVRD is the official scientific peer-reviewed journal of the American Society of Retina Specialists (ASRS), offering the highest quality and most impactful research and clinical information in the field. Join host Dr. Timothy Murray, Editor-in-Chief of JVRD, as he discusses cutting-edge developments featured in JVRD with the lead authors, who share clinical pearls and explore their significance in advancing patient care.